Home › New Analysis from Investigational IMPROVE-IT Study Shows VYTORIN (ezetimibe/simvastatin) Reduced Total (Initial and Recurrent) Cardiovascular Events More than Simvastatin Alone in Patients Presenting with Acute Coronary Syndromes
 

Keywords :   


New Analysis from Investigational IMPROVE-IT Study Shows VYTORIN (ezetimibe/simvastatin) Reduced Total (Initial and Recurrent) Cardiovascular Events More than Simvastatin Alone in Patients Presenting with Acute Coronary Syndromes

2015-03-16 20:30:00| Merck.com - Product News

Dateline City: SAN DIEGO SAN DIEGO--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced results from a pre-specified exploratory analysis of the investigational IMPROVE-IT study of more than 18,000 patients presenting with acute coronary syndromes. Language: English Contact: MerckMedia:Pamela Eisele, 267-305-3558orMichael Close, 267-305-1211orInvestors:Justin Holko, 908-740-1879 Ticker Slug: Ticker: MRK Exchange: NYSE read more

Tags: with total events study

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news
»
20.05Ryanair profits surge after fares climb by 20%
20.05Vidzemes TV expands with PlayBox Neo Channel-in-a-Box playout
20.05ocilion enhances user experience with Simply.TV metadata
20.05Vantiva RDK device shipments exceed 125 million
20.05VinFast first with Sony Pictures in-car service
20.05LG Ad Solutions to adopt Unified ID 2.0
20.05Eastern North Pacific Tropical Weather Outlook
20.05Atlantic Tropical Weather Outlook
More »